Merck KGaA posts strong sales and earnings growth for 2012

7 March 2013

Germany’s Merck KGaA today reported financial results for 2012 showing 8.7% growth in total revenues to 11.17 billion euros ($14.50 billion), driven by its pharmaceutical business Merck Serono, where sales advanced 8.2% to 6.41 billion euros, Merck Millipore at 2.60 billion euros, +9%, performance materials at 1.67 billion euros, +14.3%, and consumer health at 473 million euros.

Earnings before interest, tax, depreciation and amortization (EBITDA) pre one-time items grew 8.9% to 2.96 billion euros. Net income came in at 566.7 million euros (-6.6%), or 7.61 per share pre one-time items, a rise of 12.1%. Free cash flow increased 42%; and net debt was cut by 1.6 billion euros to 1.9 billion euros. The company expects group sales to grow organically at a moderate pace in both 2013 and 2014. EBITDA pre one-time items expected to increase faster than sales.

Fourth-quarter income more than doubles

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK